0
0
Home > Pharmaceuticals >  ESG (Environmental, Social, and Governance) in Healthcare – Thematic Research

ESG (Environmental, Social, and Governance) in Healthcare – Thematic Research

ESG is more important than ever

Sustainability or environmental, social, and governance (ESG) is one of the most important themes for 2021 and the next decade. Sustainability used to be just about saving the planet. Today it has morphed into an umbrella term covering all environmental, social, and governance issues.

Citizens, governments, regulators, and the media are turning the spotlight on corporations and demanding action. Social inequality, corruption, tax avoidance, and a lack of action on climate change are all issues that companies must now address head-on, in full public view. All aspects of ESG are important, and across the healthcare industry, companies must excel across all three. A GlobalData poll of pharma industry professionals found that over 40% of respondents believed that environmental issues need to be addressed the most, followed by approximately 30% for social and 25% for governance issues.

Immediate ESG action will create tomorrow’s winners

Some CEOs have been reluctant to embrace sustainability principles because of the age-old view that it will hurt profits. However, the evidence suggests that those companies that are too slow to improve their approach to ESG will see an exodus of customers and a drop in profits. Stakeholders are also becoming more conscious of ESG, and companies taking significant action now will be rewarded in the long term. Many players across the healthcare industry, including pharma, medical devices, and healthcare providers, are announcing new ESG goals and issuing pledges to ensure more sustainable practices are implemented and upheld.

COVID-19 has led to a greater focus on ESG across healthcare. As the world endures the ongoing effects of COVID-19, ESG needs to be at the core of any company or institution that wants to continue to provide quality care and services with ever-increasing healthcare costs and economic uncertainty. The heroic efforts of healthcare providers and hospitals during COVID-19 and the rapid development of vaccines and tests have transformed public opinion of the healthcare industry. This is particularly true for pharma, which has struggled with a poor reputation for years due to high drug prices and unethical business practices.

Scope

This report focuses on the importance of ESG sustainability throughout the healthcare industry.

ESG thematic research offers a detailed analysis of the various sustainability factors that are of importance to stakeholders and why businesses throughout the value chain should focus on improving their ESG responsibility. The research includes insightful industry analysis of ESG factors and key use cases highlighting how healthcare players are integrating sustainable initiatives.

Key Highlights

Some CEOs have been reluctant to embrace sustainability principles because of the age-old view that it will hurt profits. However, the evidence suggests that those companies that are too slow to improve their approach to ESG will see an exodus of customers and a drop in profits. Stakeholders are also becoming more conscious of ESG, and companies taking significant action now will be rewarded in the long term. Many players across the healthcare industry, including pharma, medical devices, and healthcare providers, are announcing new ESG goals and issuing pledges to ensure more sustainable practices are implemented and upheld.

COVID-19 has led to a greater focus on ESG across healthcare. As the world endures the ongoing effects of COVID-19, ESG needs to be at the core of any company or institution that wants to continue to provide quality care and services with ever-increasing healthcare costs and economic uncertainty. The heroic efforts of healthcare providers and hospitals during COVID-19 and the rapid development of vaccines and tests have transformed public opinion of the healthcare industry. This is particularly true for pharma, which has struggled with a poor reputation for years due to high drug prices and unethical business practices.

Reasons to Buy

Corporations: Helps CEOs in all industries understand the disruptive threats to their competitive landscape.

Investors: Helps fund managers focus their time on the most exciting investment opportunities in global Healthcare.

Whilst most investment research is underpinned by backwards looking company valuation models, GlobalData’s thematic methodology identifies which companies are best placed to succeed in a future filled with multiple disruptive threats. Compared to all our rival thematic research houses, our unique differentiator is that our thematic engine has a proven track record of predicting leaders and challengers.

Gain an in-depth understanding of how ESG factors are shaping the industry in the top spending countries across the world and identify the opportunities offered by each of them.

Strengthen your understanding of the market in terms of industry trends, challenges and the latest technological developments, among others.

Companies Mentioned

GlaxoSmithKline (GSK), UnitedHealth Group, Philips, Eli Lilly, St. James Hospital, Roche, CVS Health, Thermo Fischer Scientific, Gilead, Purdue Pharma, Cygnet Healthcare, Danaher, HCA Healthcare, Novartis, NMC Healthcare, Fresenius Medical Care

Table of Contents

Executive Summary

GlobalData’s ESG framework

Trends

The ESG Action Feedback Loop

Case studies

ESG timeline

Companies

Sector scorecard

Glossary

Further reading

Our thematic research methodology

About GlobalData

Contact Us

List of Tables

Technology trends

Industry trends

Macroeconomic trends

Healthcare Companies

Medical Device Companies

Pharma Companies

Drug development sector scorecard

Thematic screen

Valuation screen

Glossary

Further reading-GlobalData reports

List of Figures

GlobalData’s ESG framework

Contributing factors and mitigating actions form part of our ESG framework

ESG Action Feedback Loop

GlobalData’s ESG framework – environmental challenges

GlobalData’s ESG framework – social challeges

GlobalData’s ESG framework – governance challenges

The ESG story

    Pricing

Discounts available for multiple purchases.

reportstore@globaldata.com
+44 20 7947 2745

Join our mailing list

Saved reports